Creekside Family Practice Reports 90% Online Appointment Scheduling with eClinicalWorks EHR and healow

eClinicalWorks®, the leading provider of cloud-based EHR systems, has announced that Creekside Family Practice is effectively using eClinicalWorks EHR and healow® Open Access® for online appointment scheduling. The practice has reported that 90% of their monthly appointments are scheduled through…

Read MoreCreekside Family Practice Reports 90% Online Appointment Scheduling with eClinicalWorks EHR and healow

Guardant Health to Ring Nasdaq Bell on August 28 for Shield™ Colorectal Cancer Test Launch

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology firm, will ring the Nasdaq opening bell at MarketSite in Times Square, New York on Wednesday, August 28, 2024. “Today, we celebrate the launch of Shield, our FDA-approved blood-based test for…

Read MoreGuardant Health to Ring Nasdaq Bell on August 28 for Shield™ Colorectal Cancer Test Launch

Simulations Plus Restructures Business Units to Support Growth After Recent Acquisitions

Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation, simulation-enabled performance, intelligence solutions, and medical communications for the biopharma industry, has announced an optimization of its business unit and leadership structure. This strategic move, effective August 30, 2024, is…

Read MoreSimulations Plus Restructures Business Units to Support Growth After Recent Acquisitions

Techstars, Johns Hopkins, and CareFirst Launch Healthcare AI Accelerator in Baltimore

Techstars, Johns Hopkins University, and CareFirst BlueCross BlueShield (CareFirst) have announced a new collaboration to launch a healthcare accelerator program. This initiative aims to support early-stage entrepreneurs developing AI-driven solutions for improving care pathways. Techstars AI Health Baltimore, powered by…

Read MoreTechstars, Johns Hopkins, and CareFirst Launch Healthcare AI Accelerator in Baltimore

Invenra’s Antibody INV724 Gains FDA Rare Pediatric and Orphan Drug Designations for Neuroblastoma

Invenra Inc. is excited to announce that its innovative bispecific antibody, INV724, designed for the treatment of neuroblastoma, has received both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations from the U.S. Food and Drug Administration (FDA). These designations…

Read MoreInvenra’s Antibody INV724 Gains FDA Rare Pediatric and Orphan Drug Designations for Neuroblastoma

VION Biosciences Acquires Echelon Biosciences, a Leader in Specialty Lipids and Nanoparticles

VION Biosciences, a life science platform company specializing in specialty reagents for research, diagnostics, and drug discovery, has announced the acquisition of Echelon Biosciences, a Salt Lake City-based supplier known for its critical materials, including lipid-based excipients. This acquisition marks…

Read MoreVION Biosciences Acquires Echelon Biosciences, a Leader in Specialty Lipids and Nanoparticles